CONFERENCES & MEETINGS
CONFERENCES & MEETINGS IN 2017
THE LIVER MEETING® 2017
American Association for the Study of Liver Diseases
Walter E. Washington Convention Center, Washington, DC
October 20-24, 2017
Sponsored by the American Association for the Study of Liver Diseases (AASLD), the Meeting has a focus on the science and clinical practice of hepatology, providing the latest information on hepatology research and patient care. Hepatologists from around the world exchange the latest research, discuss new developments in treatment outcomes, and network with other experts in the field.
DRUG-INDUCED LIVER INJURY CONFERENCE
FDA/CDER-Critical Path Institute
The US Food and Drug Administration, Center for Drug Evaluation and Research (FDA/CDER) and Critical Path Institute (C-Path) co-sponsor an annual Drug-Induced Liver Injury Conference. The program is endorsed by the National Institutes of Health, Drug-Induced Liver Injury Network (DILIN), American Association for the Study of Liver Diseases (AASLD), Hamner-UNC Institute for Drug Safety Sciences, and the Pharmaceutical Research and Manufacturers of America (PhRMA). The academic-industry-government Conference provides a forum to discuss new findings and thinking about DILI, including presentation by experts in clinical hepatology, toxicology, and other scientific fields. Presentations from these conferences can be found on the AASLD website.
2017 DILI CONFERENCE XVII
FDA/CDER-Critical Path Institute
Meeting Theme: Asymmetry of Drug Safety and Efficacy in Clinical Trials with DILI -
Toward Quantitative Estimate of Net Benefit to Patients
College Park Marriott Hotel and Conference Center
June 6-7, 2017
Previous DILI Conference Summaries
- Drug-Induced Liver Injury Conference, 2016, Agenda
- Drug-Induced Liver Injury Conference, 2015, Agenda
- Drug-Induced Liver Injury Conference, 2014
- Drug-Induced Liver Injury Conference, 2013
- AASLD-FDA-NIH-PhRMA- Hepatotoxicity Special Interest Group Conference, 2012
- AASLD-FDA-NIH-PhRMA- Hepatotoxicity Special Interest Group Conference, 2011
- AASLD-FDA-NIH-PhRMA- Hepatotoxicity Special Interest Group Conference, 2010
- AASLD-FDA-NIH-PhRMA- Hepatotoxicity Special Interest Group Conference, 2009
- AASLD-FDA-NIH-PhRMA- Hepatotoxicity Special Interest Group Conference, 2008
- AASLD-FDA-NIH-PhRMA- Hepatotoxicity Special Interest Group Conference, 2007
- AASLD-FDA-NIH-PhRMA- Hepatotoxicity Steering Group Meeting, 2006
- FDA-PhRMA-AASLD Hepatotoxicity Steering Committee Meeting, 2005
- Hepatotoxicity Steering Group Meeting, 2004
- Hepatocoxicity Steering Group Meeting, 2003
- Drug-Induced Liver Injury: A National and Global Problem, 2001
- Drug-Induced Liver Injury: Mechanisms and Test Systems. NIH Conference at Lister Hill Center, October 17-18, 2000 (summarized in: Hepatology 2001 Apr;33(4):1009-13)
- CDER Staff College Course: Drugs and the Liver: What They Do to Each Other. April 19-20, 1999. Course agenda (PDF - 82KB)
CONFERENCE & MEETING SUMMARIES
LIVER INJURY FROM HERBAL AND DIETARY SUPPLEMENTS
NIH-AASLD Workshop
Lister Hill Auditorium, NIH Campus, Bethesda, MD
May 4-5, 2015
A National Institutes of Health Workshop co-sponsored by the American Association for the Study of Liver Diseases (AASLD), US Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and US Department of Agriculture (USDA). The Workshop purpose is to evaluate the use of herbals and dietary supplements and the problem of their occasional hepatotoxicity.
CLINICAL ALERTS, NEWS, UPDATES
-
FDA Drug-Induced Liver Toxicity Page (HHS/FDA)
-
NIH Clinical Alerts and Advisories (HHS/NIH)
Top of page
PDF documents are best viewed with the free Adobe® Reader